2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Mortality due to non-AIDS-defining cancers among people living with HIV in Spain over 18 years of follow-up

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Our aim was to describe non-AIDS-defining cancer (NADC) mortality among people living with HIV (PLWH), to compare it with that of the general population, and to assess potential risk factors.

          Methods

          We included antiretroviral-naive PLWH from the multicentre CoRIS cohort (2004–2021). We estimated mortality rates and standardised mortality ratios (SMRs). We used cause-specific Cox models to identify risk factors.

          Results

          Among 17,978 PLWH, NADC caused 21% of all deaths observed during the follow-up. Mortality rate due to NADC was 1.58 (95%CI 1.36, 1.83) × 1000 person-years and lung and liver were the most frequent cancer-related causes of death. PLWH had 79% excess NADC mortality risk compared to the general population with the highest SMR found for Hodgkin lymphoma, anal and liver cancers. The SMRs decreased with age and were the highest in age groups under 50 years. The most important prognostic factor was low CD4 count, followed by smoking, viral hepatitis and HIV transmission through heterosexual contact or injection drug use.

          Conclusion

          Non-AIDS cancers are an important cause of death among PLWH. The excess mortality related to certain malignancies and the association with immunodeficiency, smoking, and coinfections highlights the need for early detection and treatment of cancer in this population.

          Supplementary Information

          The online version contains supplementary material available at 10.1007/s00432-023-05500-9.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: found

          Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration

          With the advent of effective antiretroviral treatment, the life expectancy for people with HIV is now approaching that seen in the general population. Consequently, the relative importance of other traditionally non-AIDS-related morbidities has increased. We investigated trends over time in all-cause mortality and for specific causes of death in people with HIV from 1999 to 2011.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Spectrum of cancer risk among HIV-infected people in the United States during the modern antiretroviral therapy era: a population-based registry linkage study

            Background Monitoring cancer risk among HIV-infected people in the modern antiretroviral therapy (ART) era is critical given their elevated risk for many cancers and prolonged survival with immunosuppression, ART exposure, and aging. Our study described cancer risk in HIV-infected people in the United States relative to the general population. Methods Utilizing data from linked population-based HIV and cancer registries (nine areas; 1996–2012), we calculated standardized incidence ratios (SIRs). We tested SIR differences by AIDS status and over time using Poisson regression. Findings Among 448,258 HIV-infected people, risk was elevated (p<0·0001) for cancer overall (SIR 1·69; 95%CI: 1·67–1·72), AIDS-defining cancers (Kaposi sarcoma [498; 478–519], non-Hodgkin lymphoma [11·5; 11·1–11·9], and cervix [3·24; 2·94–3·56]), most other virus-related cancers (e.g., anus [19·1; 18·1–20·0], liver [3·21; 3·02–3·41], and Hodgkin lymphoma [7·70; 7·20–8·23]), and some virus-unrelated cancers (e.g., lung [1·97; 1·89–2·05]), but not for other common cancers. Risk for several cancers was higher after AIDS onset and declined across calendar periods. After multivariable adjustment, SIRs decreased significantly across 1996–2012 for six cancers (Kaposi sarcoma, two non-Hodgkin lymphoma subtypes, anus, liver, and lung) but remained elevated in the latest period. SIRs did not increase over time for any cancer. Interpretation Risks for several virus-related cancers and lung cancer declined among HIV-infected people, likely reflecting ART expansion since 1996. Despite declines, risk for many cancers remain elevated in the modern treatment era. Funding National Cancer Institute.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort

              Deaths in HIV-positive people have decreased since the introduction of highly active antiretroviral therapy (HAART) in 1996. Fewer AIDS-related deaths and an ageing cohort have resulted in an increase in the proportion of HIV patients dying from non-AIDS-related disorders. Here we describe mortality and causes of death in people diagnosed with HIV in the HAART era compared with the general population.
                Bookmark

                Author and article information

                Contributors
                mrava@isciii.es
                Journal
                J Cancer Res Clin Oncol
                J Cancer Res Clin Oncol
                Journal of Cancer Research and Clinical Oncology
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0171-5216
                1432-1335
                26 November 2023
                26 November 2023
                2023
                : 149
                : 20
                : 18161-18171
                Affiliations
                [1 ]Grupo de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario Infanta Sofía, FIIB HUIS HHEN, ( https://ror.org/05dfzd836) Madrid, Spain
                [2 ]CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, ( https://ror.org/00ca2c886) Madrid, Spain
                [3 ]Department of Medicine, Universidad Europea de Madrid, ( https://ror.org/04dp46240) Madrid, Spain
                [4 ]GRID grid.411093.e, ISNI 0000 0004 0399 7977, Hospital General Universitario de Elche and Universidad Miguel Hernández, ; Alicante, Spain
                [5 ]Hospital Universitario Ramón y Cajal, IRYCIS, ( https://ror.org/050eq1942) Madrid, Spain
                [6 ]GRID grid.410526.4, ISNI 0000 0001 0277 7938, Hospital Gregorio Marañón Servicio de Enfermedades Infecciosas/Microbiología Clínica Instituto de Investigación Gregorio Marañón, ; Madrid, Spain
                [7 ]Hospital Universitario La Paz, ( https://ror.org/01s1q0w69) Madrid, Spain
                [8 ]GRID grid.411083.f, ISNI 0000 0001 0675 8654, Infectious Diseases Department, , Vall d’Hebron Research Institute (VHIR), Hospital Universitari Vall d’Hebron, ; Barcelona, Spain
                [9 ]Servicio de Medicina Interna, Hospital Clínico Universitario de Valladolid, ( https://ror.org/04fffmj41) Valladolid, Spain
                [10 ]Infectious Diseases Unit, Hospital Universitario Central de Asturias and Group of Translational Research in Infectious Diseases, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), ( https://ror.org/05xzb7x97) Oviedo, Spain
                [11 ]GRID grid.507938.0, Hospital de La Marina Baixa, ; Alicante, Spain
                [12 ]GRID grid.413448.e, ISNI 0000 0000 9314 1427, Centro Nacional de Epidemiologia, , Instituto de Salud Carlos III, ; Madrid, Spain
                Author information
                http://orcid.org/0000-0003-2260-9370
                Article
                5500
                10.1007/s00432-023-05500-9
                10725373
                38008809
                25c08cb9-df34-4b88-a8d4-54dc12a43e55
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 25 July 2023
                : 30 October 2023
                Funding
                Funded by: Gilead Scholarship Program for Biomedical Research
                Award ID: GLD19_00106
                Award Recipient :
                Funded by: ISCIII- Miguel Servet
                Award ID: CP19CIII - 00002 contract
                Award Recipient :
                Funded by: Instituto de Salud Carlos III
                Categories
                Research
                Custom metadata
                © Springer-Verlag GmbH Germany, part of Springer Nature 2023

                Oncology & Radiotherapy
                cancer,mortality,hiv,cohort study
                Oncology & Radiotherapy
                cancer, mortality, hiv, cohort study

                Comments

                Comment on this article